Frier Levitt has identified an alarming trend in government investigations of pharmacies whereby Office of Inspector General (“OIG”) and Drug Enforcement Administration (“DEA”) issue subpoenas simultaneously or almost at the same time. ... Read More
Blogs & Articles | Community, Retail Pharmacies | Life Sciences | Regulatory Compliance, including FDA, DEA and HIPAA

A drug pricing program authorized under a 1992 amendment to the Public Health Service Act (Pub. L. 102-585 (1992); 42 U.S.C. § 256b), named 340B, requires drug manufacturers, in exchange for having its drugs covered by Medicaid, to sell outpatient... Read More
Blogs & Articles | Community, Retail Pharmacies | Life Sciences | Section 340B In-House and Contract Pharmacies

On June 9, 2020 the U.S. Department Health and Human Services (“DHHS”) announced that it was allocating a total of $15 Billion in Provider Relief Fund payments to Medicaid or Children’s Health Insurance Program (CHIP) providers who have been... Read More
Blogs & Articles | COVID-19 Resources | Healthcare Law | Medicare and Insurance Audits

Last week, the U.S. Department of Health and Human Services ("HHS") announced that all Medicare-participating providers with COVID-19 related losses are eligible for a second round of funding, totaling $20 billion, from the CARES Act-authorized... Read More
COVID-19 Resources | Employment Matters | Healthcare Law | Pharmacy Law

In response to the COVID-19 emergency, on March 13, the secretary of the US Department of Health and Human Services identified certain areas of law under Medicare, Medicaid and Children’s Health Insurance Program that may be waived during the... Read More
Blogs & Articles | COVID-19 Resources | Healthcare Law | White Collar Defense and Government Investigation